These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25409261)

  • 1. Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma.
    Boussiotis VA
    N Engl J Med; 2014 Dec; 371(23):2230-2. PubMed ID: 25409261
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
    N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.
    Chan TA; Wolchok JD; Snyder A
    N Engl J Med; 2015 Nov; 373(20):1984. PubMed ID: 26559592
    [No Abstract]   [Full Text] [Related]  

  • 4. Skin cancer. Benefiting from CTLA-4 blockade--a genetic rationale.
    Errico A
    Nat Rev Clin Oncol; 2015 Jan; 12(1):4. PubMed ID: 25488393
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic basis for clinical response to CTLA-4 blockade.
    Melero I; Lasarte JJ
    N Engl J Med; 2015 Feb; 372(8):783. PubMed ID: 25693025
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic basis for clinical response to CTLA-4 blockade.
    Snyder A; Wolchok JD; Chan TA
    N Engl J Med; 2015 Feb; 372(8):783. PubMed ID: 25693024
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.
    Queirolo P; Morabito A; Laurent S; Lastraioli S; Piccioli P; Ascierto PA; Gentilcore G; Serra M; Marasco A; Tornari E; Dozin B; Pistillo MP
    Cancer Invest; 2013 Jun; 31(5):336-45. PubMed ID: 23641913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
    Smyth MJ; Yagita H; McArthur GA
    J Clin Oncol; 2016 Apr; 34(12):e104-6. PubMed ID: 25311221
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
    Letendre P; Monga V; Milhem M; Zakharia Y
    Future Oncol; 2017 Mar; 13(7):625-636. PubMed ID: 27882779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
    Buchbinder EI; McDermott DF
    Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CANCER. The odds of immunotherapy success.
    Gubin MM; Schreiber RD
    Science; 2015 Oct; 350(6257):158-9. PubMed ID: 26450194
    [No Abstract]   [Full Text] [Related]  

  • 19. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
    Vétizou M; Pitt JM; Daillère R; Lepage P; Waldschmitt N; Flament C; Rusakiewicz S; Routy B; Roberti MP; Duong CP; Poirier-Colame V; Roux A; Becharef S; Formenti S; Golden E; Cording S; Eberl G; Schlitzer A; Ginhoux F; Mani S; Yamazaki T; Jacquelot N; Enot DP; Bérard M; Nigou J; Opolon P; Eggermont A; Woerther PL; Chachaty E; Chaput N; Robert C; Mateus C; Kroemer G; Raoult D; Boneca IG; Carbonnel F; Chamaillard M; Zitvogel L
    Science; 2015 Nov; 350(6264):1079-84. PubMed ID: 26541610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.